Abstract
The prevalence of chronic obstructive pulmonary disease (COPD) is increasing and is now the third most common cause of death in the United States. It is estimated that half of all people in the United States with COPD have not been diagnosed, reflecting factors that include patient delay in seeking help despite symptoms and physician perception that only smoking cessation can improve the course of the disease. Primary care physicians are best placed to identify undiagnosed patients with mild or moderate COPD. Recent evidence from large randomized clinical trials demonstrates that pharmacologic treatments such as tiotropium and salmeterol/fluticasone can benefit patients with mild and moderate COPD, improving lung function, reducing the risk of exacerbations and improving health status. Primary care physicians can help patients and reduce the burden of COPD on healthcare systems by actively assessing patients they suspect may have COPD and treating those diagnosed.
Keywords: Chronic obstructive pulmonary disease, diagnosis, FEV1, smoking cessation, chronic smoking, Diagnosis of COPD
Current Respiratory Medicine Reviews
Title:Medical Treatment of COPD Patients with Mild and Moderate Airflow Obstruction
Volume: 8 Issue: 6
Author(s): Gary T. Ferguson and Leonard Fromer
Affiliation:
Keywords: Chronic obstructive pulmonary disease, diagnosis, FEV1, smoking cessation, chronic smoking, Diagnosis of COPD
Abstract: The prevalence of chronic obstructive pulmonary disease (COPD) is increasing and is now the third most common cause of death in the United States. It is estimated that half of all people in the United States with COPD have not been diagnosed, reflecting factors that include patient delay in seeking help despite symptoms and physician perception that only smoking cessation can improve the course of the disease. Primary care physicians are best placed to identify undiagnosed patients with mild or moderate COPD. Recent evidence from large randomized clinical trials demonstrates that pharmacologic treatments such as tiotropium and salmeterol/fluticasone can benefit patients with mild and moderate COPD, improving lung function, reducing the risk of exacerbations and improving health status. Primary care physicians can help patients and reduce the burden of COPD on healthcare systems by actively assessing patients they suspect may have COPD and treating those diagnosed.
Export Options
About this article
Cite this article as:
T. Ferguson Gary and Fromer Leonard, Medical Treatment of COPD Patients with Mild and Moderate Airflow Obstruction, Current Respiratory Medicine Reviews 2012; 8 (6) . https://dx.doi.org/10.2174/1573398X11208060009
DOI https://dx.doi.org/10.2174/1573398X11208060009 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
Call for Papers in Thematic Issues
Exposure to PM2.5 components is associated with respiratory diseases
Through continuous research on the relationship between risk factors and health, it has been found that air pollution, especially atmospheric particulate matter pollution, has become one of the main sources of global disease burden. From 1990 to 2022, the concentration of atmospheric particulate matter pollution has increased by more than ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Bioanalytical Method Development and Validation for the Determination of Vasopressin Receptor Antagonist Conivaptan in Mouse Plasma at NanoLevel and its Pharmacokinetic Application
Current Analytical Chemistry Signaling Epicenters: The Role of Caveolae and Caveolins in Volatile Anesthetic Induced Cardiac Protection
Current Pharmaceutical Design The Renin-Angiotensin Systems: Evolving Pharmacological Perspectives for Cerebroprotection
Current Pharmaceutical Design Relevance of Sphingolipids in the Pleiotropic Protective Effects of High-Density Lipoproteins
Current Pharmaceutical Design An Old Drug with a New Purpose: Cardiovascular Actions of Acetaminophen (Paracetamol)
Current Drug Targets - Cardiovascular & Hematological Disorders Toll-Like Receptors and Myocardial Ischemia/Reperfusion, Inflammation, and Injury
Current Cardiology Reviews Exercise Induced Cardioprotection: An Overview of a Unique Form of Preconditioning
Current Cardiology Reviews Roles of p38-MAPK in Insulin Resistant Heart: Evidence from Bench to Future Bedside Application
Current Pharmaceutical Design Curcumin Potentiates The Ability of Sunitinib to Eliminate the VHL-lacking Renal Cancer Cells 786-O: Rapid Inhibition of Rb Phosphorylation as a Preamble to Cyclin D1 Inhibition
Anti-Cancer Agents in Medicinal Chemistry Nocturnal Hypertension and Chronic Kidney Disease
Current Hypertension Reviews Nanotechnology and Atherosclerosis Imaging: Emerging Diagnostic and Therapeutic Applications
Recent Patents on Cardiovascular Drug Discovery Vascular Endothelial Growth Factor (VEGF) Signaling in Tumour Vascularization: Potential and Challenges
Current Vascular Pharmacology Looking for Organ Damages Due to Anabolic-androgenic Steroids (AAS): Is Oxidative Stress the Culprit?
Mini-Reviews in Organic Chemistry Pathophysiology of Chronic Obstructive Pulmonary Disease
Current Respiratory Medicine Reviews Cardiac Regeneration: Stem Cells and Beyond
Current Medicinal Chemistry Hypoxia-Inducible Factor-1: A Molecular Hint of Physiological Changes in the Carotid Body During Long-Term Hypoxemia?
Current Drug Targets - Cardiovascular & Hematological Disorders Myxedema Heart Disease: A Rare Disease Entity: Case Report and Brief Review of the Literature
Current Hypertension Reviews Modulation of Matrix Metalloproteinase Activity by Tobacco Cigarette Smoke
Current Chemical Biology Stroke Prevention in Patients with Non-valvular Atrial Fibrillation: New Insight in Selection of Rhythm or Rate Control Therapy and Impact of Mean Platelet Volume
Current Pharmaceutical Design The Need for Physiologically Relevant Peroxisome Proliferator-Activated Receptor-gamma (PPAR-γ) Ligands
Endocrine, Metabolic & Immune Disorders - Drug Targets